B.Sc. [Microbiology] (University of Alberta), Ph.D. [Microbiology] (University of British Columbia)
Professor, Department of Pathology and Laboratory Medicine, University of British Columbia
Research InterestsAging; lipid metabolism; Neurodegeneration; neuroscience; pathology
Dr. Wellington’s major research interests are on both genetic and environmental factors that modulate risk for Alzheimer Disease (AD), the most common dementia. An increasingly recognized environment risk factor for dementia includes a history of traumatic brain injury (TBI). Current projects include understanding how injury severity, number of injuries, and age at injury all affect dementia risk, and understanding how the neuropathology and clinical presentation of TBI-related syndromes overlap with classical dementias. Over two million TBIs occur annually in North America, with rapidly increasing public concern over the long-term effects of concussion on brain health during development and aging. Existing animal models of TBI, however, fail to replicate the mechanics of most real-life human TBIs, which are caused by sharp, angular and/or linear accelerations or decelerations of a freely moving intact head.
Working with biomechanical engineers at ICORD, Dr. Wellington and her colleagues have developed a transformative new model of rodent closed head TBI, called CHIMERA (Closed Head Injury Model of Engineered Rotational Acceleration) that was specifically designed to overcome the caveats that limit the translational relevance of existing TBI models. CHIMERA’s innovation lies in its ability to generate, in a biomechanically controlled and reproducible manner, a wide range of TBI severity with completely free head movement, where head motion analyses are integrated with behavioral and neuropathological outcomes.
Current Lab Members
|Ph.D. Students||Masters Students||Research Staff|
|Pantea Azadpour||Elyn Rowe||Anna Wilkinson|
|Emily Button*||Lexi Busse||Sophie Stukas|
|Tiffany Cameron||Jasmine Gill||Jerome Robert|
|Asma Bashir*||Tara Caffrey|
- Hoiland, RL et al.. 2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.. Br. J. Haematol. doi: 10.1111/bjh.16961.
- Cable, J et al.. 2020. Alternatives to amyloid for Alzheimer's disease therapies-a symposium report.. Ann. N. Y. Acad. Sci. doi: 10.1111/nyas.14371.
- England, JT et al.. 2020. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.. Blood Rev. doi: 10.1016/j.blre.2020.100707.
- Zhao, W et al.. 2020. Axl receptor tyrosine kinase is a regulator of apolipoprotein E.. Mol Brain. doi: 10.1186/s13041-020-00609-1.
- Robert, J et al.. 2020. Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E.. Mol Neurodegener. doi: 10.1186/s13024-020-00366-8.